Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: A 3-year randomized placebo-controlled trial

Journal of Bone and Mineral Research

Volumn 21, Issue 2, 2006, Pages 300-306

  Chevrel, Guillaume ^a,c   Schott, Anne Marie ^a   Fontanges, Elisabeth ^a   Charrin, Jeanne E ^a   Lina Granade, Geneviève ^a   Duboeuf, François ^b   Garnero, Patrick ^b   Arlot, Monique ^b   Raynal, Claude ^a   Meunier, Pierre J ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b INSERM   (France)

^c Department of Rheumatology and Bone Diseases ^*  (France)

Author keywords

Bisphosphonate; Bone densitometry; Clinical trials; Osteogenesis imperfecta

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CALCIUM ION; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; CREATININE; OSTEOCALCIN; PARATHYROID HORMONE; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; BONE DENSITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EAR NOSE THROAT DISEASE; EYE DISEASE; FEMALE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEMATEMESIS; HEMATOCHEZIA; HIP FRACTURE; HUMAN; LIVER DYSFUNCTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; OSSIFICATION; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; UROGENITAL TRACT DISEASE; VERTEBRA FRACTURE;

ADMINISTRATION, ORAL; ADULT; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; COLLAGEN; COLLAGEN TYPE I; DENSITOMETRY, X-RAY; FEMALE; FRACTURES, BONE; HEARING LOSS; HIP; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOGENESIS IMPERFECTA; PAIN; PEPTIDES; PLACEBOS; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 33144463953     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.051015     Document Type: Article

References (25)

1. Sillence DO, Senn A, Danks DM 1979 Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101-116.
2. Rauch F, Glorieux FH 2004 Osteogenesis imperfecta. Lancet 363:1377-1385.
3. Sykes B, Ogilvie D, Wordsworth P, Wallis G, Mathew C, Beighton P, Nicholls A, Pope FM, Thompson E, Tsiporas P 1990 Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL 1A1 and COL 1A2. Am J Hum Genet 46:293-307.
4. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C 1987 Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360-363.
5. Huaux JP, Lokietek W 1988 Is APD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthop 8:71-72.
6. Brumsen C, Hamdy NA, Papapoulos SE 1997 Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 76:266-283.
7. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952.
8. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH 2000 Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:1846-1850.
9. Astrom E, Soderhall S 2002 Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86:356-364.
10. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH 2003 Osteogenesis imperfecta types I, III, and IV: Effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88:986-992.
11. Zeitlin L, Rauch F, Plotkin H, Glorieux FH 2003 Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111:1030-1036.
12. Arikoski P, Silverwood B, Tillmann V, Bishop NJ 2004 Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: Assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 34:539-546.
13. Sakkers R, Kok D, Engelbert R, Van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C 2004 Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: A 2-year randomised placebo-controlled study. Lancet 363:1427-1431.
14. Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R, Fedarko N, Santiago HT, Bober M 2003 The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int 72:103-112.
15. Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tato L 2003 Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18:126-130.
16. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443.
17. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541.
18. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124.
19. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A 2000 Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610.
20. Paterson CR, McAllion S, Stellman JL 1984 Osteogenesis imperfecta after the menopause. N Engl J Med 310:1694-1696.
21. Carter CO, Wilkinson JA 1964 Genetic and environmental factors in the etiology of congenital dislocation of the hip. Clin Orthop 33:119-128.
22. Fardellone P, Sebert JL, Bouraya M, Bonidan O, Leclercq G, Doutrellot C, Bellony R, Dubreuil A 1991 Evaluation of the calcium content of diet by frequential self-questionnaire. Rev Rhum Mal Osteoartic 58:99-103.
23. Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR 1996 Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:984-996.
24. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292-299.
25. Rauch F, Travers R, Plotkin H, Glorieux FH 2002 The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293-1299.